Anticoagulation therapy in COVID-19 patients with chronic kidney disease (Review Article)

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

SHAFIEE MOHAMMAD ALI; Hosseini Sayyideh Forough; MORTAZAVI MOJGAN; Mojtahed Zadeh Mahtab; Moradi Sanaz; Shaker Pouyan

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: JOURNAL OF RESEARCH IN MEDICAL SCIENCES (JRMS) Year:2021 | Volume:26 | Issue:- Page(s): 0-0

Download Full-Text

View:

Download:

Cites:

Information Journal Paper

Title

Anticoagulation therapy in COVID-19 patients with chronic kidney disease (Review Article)

Author(s)

Keywords

Anticoagulation therapy

chronic kidney disease

coagulation system

COVID-19

D-dimer

Abstract

Coagulopathy and derangements in the coagulation parameters are significant features of COVID‑ 19 infection, which increases the risk of disseminated intravascular coagulation, thrombosis, and hemorrhage in these patients, resulting in increased morbidity and mortality. In times of COVID‑ 19, special consideration should be given to patients with concurrent chronic kidney disease (CKD) and COVID‑ 19 (CKD/COVID‑ 19 patients) as renal dysfunction increases their risk of thrombosis and hemorrhage, and falsely affects some of the coagulation factors, which are currently utilized to assess thrombosis risk in patients with COVID‑ 19. Hence, we believe extra attention should be given to determining the risk of thrombosis and bleeding and optimizing the timing and dosage of anticoagulant therapy in this unique population of patients. CKD/COVID‑ 19 patients are considered a high‑ risk population for thrombotic events and hemorrhage. Furthermore, effects of renal function on paraclinical and clinical data should be considered during the evaluation and interpretation of thrombosis risk stratification. Individualized evaluation of clinical status and kidney function is necessary to determine the best approach and management for anticoagulant therapy, whereas there is a lack of studies about the population of CKD/COVID‑ 19 patients who need anticoagulant therapy now.

Multimedia

No record.

Cites

No record.

References

No record.

Cite

APA: Copy

Hosseini, Sayyideh Forough, MORTAZAVI, MOJGAN, Mojtahed Zadeh, Mahtab, Moradi, Sanaz, & Shaker, Pouyan. (2021). Anticoagulation therapy in COVID-19 patients with chronic kidney disease (Review Article). JOURNAL OF RESEARCH IN MEDICAL SCIENCES (JRMS), 26(-), 0-0. SID. https://sid.ir/paper/984809/en

Vancouver: Copy

Hosseini Sayyideh Forough, MORTAZAVI MOJGAN, Mojtahed Zadeh Mahtab, Moradi Sanaz, Shaker Pouyan. Anticoagulation therapy in COVID-19 patients with chronic kidney disease (Review Article). JOURNAL OF RESEARCH IN MEDICAL SCIENCES (JRMS)[Internet]. 2021;26(-):0-0. Available from: https://sid.ir/paper/984809/en

IEEE: Copy

Sayyideh Forough Hosseini, MOJGAN MORTAZAVI, Mahtab Mojtahed Zadeh, Sanaz Moradi, and Pouyan Shaker, “Anticoagulation therapy in COVID-19 patients with chronic kidney disease (Review Article),” JOURNAL OF RESEARCH IN MEDICAL SCIENCES (JRMS), vol. 26, no. -, pp. 0–0, 2021, [Online]. Available: https://sid.ir/paper/984809/en

Related Journal Papers

No record.

Related Seminar Papers

No record.

Related Plans

No record.

Recommended Workshops